PF-3758309, a potent ATP-competitive pyrrolopyrazole pan-PAK inhibitor, was reported to inhibit carcinomas, melanomas, and rhabdomyosarcomas by abrogating interactions of PAK1 and PAK4 with their corresponding substrates 14, 15, 33. This evidence concerns the gene PAK1 and carcinoma.